ArticleThe oncologist2019
Hypomagnesemia and Survival in Patients with Ovarian Cancer Who Received Chemotherapy with Carboplatin.
Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Prevention and Management of Carboplatin Nephrotoxicity.Cancers · 2026Review
- DNA-damaging chemotherapy reshapes cardiac-resident macrophage composition and function.Science immunology · 2026Article
- Hypomagnesemia Associated with Omeprazole Use in Patients Treated with Platinum Derivatives: An Exploratory Randomized Placebo-Controlled Clinical Trial.The Canadian journal of hospital pharmacy · 2026Article
- Supplementation with 2'-fucosyllactose, a prebiotic human milk oligosaccharide (HMO), in a magnesium-containing medical food reduces chemotherapy-induced mucositis in Wistar rats.Frontiers in nutrition · 2026Article
- Magnesium Depletion Score as a Prognostic Indicator in Endometrial Cancer: A Retrospective Cohort Study.Current oncology (Toronto, Ont.) · 2025Article
- Preoperative serum magnesium level as a prognostic and predictive biomarker in locally advanced gastric cancer patients receiving neoadjuvant immunochemotherapy.World journal of surgical oncology · 2025Article
- Pan-Cancer Landscape of Magnesium Homeostasis: Bulk Omics Research and Single-Cell Sequencing Validation.Biological procedures online · 2025Article
- Genetically engineered Magnesium/Manganese nanoparticles for cancer radioimmunotherapy.Journal of nanobiotechnology · 2025Article
- Association of Magnesium Deficiency and Reduction in Blood Pressure After Chemotherapy in Previously Hypertensive Cancer Patients: The Role of Chemotherapy and Magnesium Levels.Medicina (Kaunas, Lithuania) · 2025Article
- The evaluation of serum magnesium and calcium/magnesium ratio in patients with breast cancer receiving adjuvant chemotherapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Article
- Dietary Magnesium Replacement for Prevention of Hypomagnesemia in Patients With Ovarian Cancer Receiving Carboplatin-Based Chemotherapy.JCO oncology practice · 2024Article
- Article
- Oral magnesium supplements for cancer treatment-induced hypomagnesemia: Results from a pilot randomized trial.Health science reports · 2021Article
- Medical Complications and Prognostic Factors for Medically Unstable Conditions During Acute Inpatient Cancer Rehabilitation.JCO oncology practice · 2021Article
- An overview of diagnosis and management of drug-induced hypomagnesemia.Pharmacology research & perspectives · 2021Review
- Seizure and delirium secondary to carboplatin and pantoprazole therapy-induced hypomagnesemia in a cancer patient.Clinical case reports · 2021Article
- Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation.Cancer · 2021Article
- Electrolyte Disorders Induced by Antineoplastic Drugs.Frontiers in oncology · 2020Review
- Severe Hypomagnesemia in a Patient Treated Using Carboplatin Co-Administered with Vonoprazan.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundHypomagnesemia is a known side effect of several antineoplastic agents, but its impact on outcomes of patients with cancer is not well understood. We examined whether magnesium abnormalities affect survival in patients with ovarian cancer who receive chemotherapy containing carboplatin. MATERIALS AND
methodsWe included patients with advanced ovarian cancer who had undergone surgery and chemotherapy between January 1, 2004, and December 31, 2014, at our institution. Inclusion criteria were age 18 years or older, pathology of high-grade serous carcinoma, first treatment (surgery or chemotherapy) within 60 days of diagnosis, and chemotherapy containing carboplatin. The final cohort consisted of 229 patients. Vital signs and laboratory tests were recorded at baseline and during the treatment course. The associations between magnesium abnormalities (and other clinical characteristics) and survival were analyzed.
resultsThe median patient age was 64 years. Higher baseline heart rate (beats per minute; hazard ratio [HR] = 1.02,
conclusionBaseline heart rate and the frequency of hypomagnesemia episodes during treatment are prognostic of survival for patients with advanced ovarian cancer receiving carboplatin-containing chemotherapy and tumor reductive surgery. Future research is needed for strategies to detect and prevent hypomagnesemia in this patient population. IMPLICATIONS FOR PRACTICE: Despite standard laboratory tests and intravenous magnesium replacement prior to each cycle of chemotherapy, hypomagnesemia remains a common side effect of platinum-based chemotherapy. This study revealed that frequent occurrence of hypomagnesemia during the course of treatment including carboplatin-containing chemotherapy and tumor reductive surgery was strongly predictive of shorter survival in patients with advanced ovarian cancer. Strategies to effectively mitigate hypomagnesemia, such as more frequent detection, dietary recommendations, and timely replacement, should be considered in the overall cancer treatment plan for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.